Novavax signs manufacturing deal with Endo for potential COVID-19 vaccine
25 Sep 2020 / 19:14 H.
Sept 25 (Reuters) - Novavax Inc has signed an agreement with Endo International for manufacturing its experimental COVID-19 vaccine, the generic drugmaker said on Friday.
Endo said its unit Par Sterile has begun production of the final drug product, with initial batches to be used in Novavax's phase-3 clinical trial in the United States. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
Did you like this article?
